361 results on '"Shichijo, Shigeki"'
Search Results
2. Sequence Similarity between Commensal Bifidobacterium and Cytotoxic T Lymphocyte Epitope Peptides against Human Tumor-Associated Antigens
3. Feasibility Study of Personalized Peptide Vaccination for Advanced Small Cell Lung Cancer
4. Immunological evaluation of personalized peptide vaccination for patients with histologically unfavorable carcinoma of unknown primary site
5. Humoral immune responses to CTL epitope peptides from tumor-associated antigens are widely detectable in humans: A new biomarker for overall survival of patients with malignant diseases
6. From the viewpoints of clinical laboratory experts on covid19
7. Hyaluronic Acid Accelerates Tendon-to-Bone Healing After Rotator Cuff Repair
8. SART1 Gene Encoding Squamous Cell Carcinoma Antigen Recognized by Cytotoxic T Lymphocytes
9. Identification of novel Lck-derived T helper epitope long peptides applicable for HLA-A2+ cancer patients as cancer vaccine
10. Dissection and identification of regions required to form pseudoparticles by the interaction between the nucleocapsid (N) and membrane (M) proteins of SARS coronavirus
11. A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer
12. An HLA-A3-binding prostate acid phosphatase-derived peptide can induce CTLs restricted to HLA-A2 and -A24 alleles
13. Plasma level of prostate related‑antigen peptide‑reactive IgG is a prognostic factor of patients with breast cancer treated with personalized peptide vaccines
14. High expression of APOBEC3G in patients infected with hepatitis C virus
15. Identification of HER2/neu-Derived Peptides Capable of Inducing both Cellular and Humoral Immune Responses in HLA-A24 Positive Breast Cancer Patients
16. Phase II study of personalized peptide vaccination for refractory bone and soft tissue sarcoma patients
17. Expression of the SART1 tumor-rejection antigens in colorectal cancers
18. Gene expression profiles in peripheral blood as a biomarker in cancer patients receiving peptide vaccination
19. Investigation of factors associated with reduced clinical benefits of personalized peptide vaccination for pancreatic cancer
20. Early phase II study of mixed 19‐peptide vaccine monotherapy for refractory triple‐negative breast cancer
21. Identification of biomarkers for personalized peptide vaccination in 2,588 cancer patients
22. Abstract P5-04-21: Analysis of serum immune biomarkers for response to therapeutic personalized peptide vaccination in patients with metastatic breast cancer
23. Identification of peptides applicable as vaccines for HLA-A26-positive cancer patients
24. Phase I clinical study of a peptide vaccination for hepatitis C virus-infected patients with different human leukocyte antigen-class I-A alleles
25. A Peptide Derived From Hepatitis C Virus (HCV) Core Protein Inducing Cellular Responses in Patients With HCV With Various HLA Class IA Alleles
26. A unique gene having homology with the kinesin family member 18A encodes a tumour-associated antigen recognised by cytotoxic T lymphocytes from HLA-A2+ colon cancer patients
27. Erythropoietin-producing hepatocyte B6 variant-derived peptides with the ability to induce glioma-reactive cytotoxic T lymphocytes in human leukocyte antigen-A2+ glioma patients
28. Squamous cell and adeno cancer antigens recognized by cytotoxic T lymphocytes
29. Identification of epidermal growth factor receptor-derived peptides recognised by both cellular and humoral immune responses in HLA-A24 + non-small cell lung cancer patients
30. Protein-bound polysaccharide K induced apoptosis of the human Burkitt lymphoma cell line, Namalwa
31. Identification of B cell epitopes reactive to human papillomavirus type-16L1- derived peptides
32. A Gene Encoding Antigenic Peptides of Human Squamous Cell Carcinoma Recognized by Cytotoxic T Lymphocytes
33. Measurement of interferon-γ by high-throughput fluorometric microvolume assay technology system
34. A randomized, double-blind, phase III trial of personalized peptide vaccination for recurrent glioblastoma
35. Survival analysis of multiple peptide vaccination for the selection of correlated peptides in urological cancers
36. Antitumor activity of antibody against cytotoxic T lymphocyte epitope peptide of lymphocyte-specific protein tyrosine kinase
37. Mixed 20-peptide cancer vaccine in combination with docetaxel and dexamethasone for castration-resistant prostate cancer: A randomized, double-blind, placebo-controlled, phase 2 trial.
38. Personalized peptide vaccination as second‐line treatment for metastatic upper tract urothelial carcinoma
39. Feasibility study of personalized peptide vaccination for hepatocellular carcinoma patients refractory to locoregional therapies
40. A randomized phase II trial of personalized peptide vaccine with low dose cyclophosphamide in biliary tract cancer
41. Immunological evaluation of peptide vaccination for cancer patients with the HLA -A11+ or -A33+ allele
42. MP78-06 PHASE II STUDY OF PERSONALIZED PEPTIDE VACCINATION FOR METASTATIC UPPER TRACT UROTHELIAL CANCER PATIENTS REFRACTORY TO THE STANDARD CHEMOTHERAPY
43. Feasibility study of multiple HLA-class IA restricted peptide vaccines (KRM-19) for metastatic triple negative breast cancer (TNBC).
44. IgG response against prostate-related antigen as potential biomarker for personalized peptide vaccination in metastatic recurrent breast cancer.
45. Enhancement of humoral and cell mediated immune response to HPV16 L1-derived peptides subsequent to vaccination with prophylactic bivalent HPV L1 virus-like particle vaccine in healthy females
46. Phase I study of a new cancer vaccine of ten mixed peptides for advanced cancer patients
47. Personalized Kampo Medicine Facilitated Both Cytotoxic T Lymphocyte Response and Clinical Benefits Induced by Personalized Peptide Vaccination for Advanced Esophageal Cancer
48. Immunological evaluation of peptide vaccination for cancer patients with the HLA-A26 allele
49. Identification of novel L ck‐derived T helper epitope long peptides applicable for HLA ‐ A 2 + cancer patients as cancer vaccine
50. Immunological evaluation of peptide vaccination for cancer patients with the HLA‐A26 allele
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.